MX2016010137A - Functionalised benzopyran compounds and use thereof. - Google Patents

Functionalised benzopyran compounds and use thereof.

Info

Publication number
MX2016010137A
MX2016010137A MX2016010137A MX2016010137A MX2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A
Authority
MX
Mexico
Prior art keywords
functionalised
benzopyran compounds
present
cancer
compounds
Prior art date
Application number
MX2016010137A
Other languages
Spanish (es)
Other versions
MX368063B (en
Inventor
Heaton Andrew
Brown David
Kelly Graham
Original Assignee
Novogen ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd filed Critical Novogen ltd
Publication of MX2016010137A publication Critical patent/MX2016010137A/en
Publication of MX368063B publication Critical patent/MX368063B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence.
MX2016010137A 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof. MX368063B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US201461987323P 2014-05-01 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (2)

Publication Number Publication Date
MX2016010137A true MX2016010137A (en) 2017-02-15
MX368063B MX368063B (en) 2019-09-18

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010137A MX368063B (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof.

Country Status (25)

Country Link
US (2) US9701655B2 (en)
EP (1) EP2953938B1 (en)
JP (1) JP6570042B2 (en)
KR (1) KR102395543B1 (en)
CN (2) CN108484559A (en)
AU (1) AU2015213484B2 (en)
BR (1) BR112016018099B8 (en)
CA (1) CA2936012C (en)
CL (1) CL2016001937A1 (en)
DK (1) DK2953938T3 (en)
ES (1) ES2643407T3 (en)
HK (1) HK1218914A1 (en)
IL (1) IL241515B (en)
LT (1) LT2953938T (en)
MX (1) MX368063B (en)
MY (1) MY195739A (en)
NZ (1) NZ711603A (en)
PH (1) PH12016501422B1 (en)
PL (1) PL2953938T3 (en)
PT (1) PT2953938T (en)
RU (1) RU2676766C2 (en)
SA (1) SA516371583B1 (en)
SG (2) SG11201506988TA (en)
SI (1) SI2953938T1 (en)
WO (1) WO2015117202A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2953938B1 (en) * 2014-02-07 2017-08-02 Novogen Ltd. Functionalised benzopyran compounds and use thereof
HUE054998T2 (en) 2015-02-02 2021-10-28 Mei Pharma Inc Combination therapies for use in the treatment of breast cancer
US10265294B2 (en) * 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
JP2019513826A (en) * 2016-04-06 2019-05-30 ノクソファーム リミティド Improvement of radiation therapy
CN109700794B (en) * 2017-03-01 2021-01-08 浙江大学 Hydrazone structure type androgen receptor antagonist and application thereof
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN116113414A (en) * 2020-06-11 2023-05-12 梅制药公司 Combination therapy
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (en) 1981-12-21 1982-04-16 Council Scient Ind Res ISOMERS 1 AND D OF D1-3, 4-TRANS-3, 4-DIARYLCHROMANES 2, 2-DISUBSTITUES AND THEIR DERIVATIVES, THEIR PREPARATION AND THEIR USE
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
AU4329296A (en) 1995-01-13 1996-07-31 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
WO1996021442A1 (en) 1995-01-13 1996-07-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia
CZ212097A3 (en) 1995-01-20 1997-11-12 Novo Nordisk As Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of cerebral degenerative diseases
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
AU4329196A (en) 1995-01-20 1996-08-07 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
CN1207038A (en) 1996-01-11 1999-02-03 诺沃挪第克公司 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
EP0873120A1 (en) 1996-01-11 1998-10-28 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129622A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2270111A1 (en) 1996-10-28 1998-05-07 Lise Brown Christiansen Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA98681B (en) 1997-01-29 1998-07-29 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibition senescense-associated motor impairment
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
CA2345079C (en) * 1998-09-23 2011-06-21 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2001007031A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
AU2001296119A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Estrogen receptor-beta ligands
JP4256679B2 (en) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド How to treat restenosis
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
JPWO2004108944A1 (en) 2003-06-04 2006-07-20 三菱瓦斯化学株式会社 Method for producing optically active chromancarboxylic acid ester
EP1686981A4 (en) * 2003-11-19 2011-02-23 Novogen Res Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
CN101056868B (en) 2004-09-21 2012-05-02 马休爱德华兹股份有限公司 Substituted chroman derivatives, medicaments and use in therapy
ES2377073T3 (en) * 2004-09-21 2012-03-22 Marshall Edwards, Inc. Substituted Chroman Derivatives, Medicines and Therapy Use
EP1809618B1 (en) * 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4976649B2 (en) 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． Compound
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
US20090221564A1 (en) 2006-02-21 2009-09-03 Trigen Limited Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (en) 2006-12-31 2011-09-14 南华大学 Novel isoflavone nicotinic acid ester derivatives, preparing method and use thereof
CA2738328A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
US20100130598A1 (en) 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
JP6013349B2 (en) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CN102153535A (en) 2011-03-04 2011-08-17 中国海洋大学 Benzopyranyl-3-alcohol esterified derivative serving as antineoplastic multidrug resistance inhibitor and preparation method and application of benzopyranyl-3-alcohol esterified derivative
US20120251630A1 (en) 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
WO2013026942A1 (en) * 2011-08-25 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Tubulin binding agents
WO2013184755A2 (en) 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
CN103408528B (en) 2013-08-13 2015-04-29 浙江大学 Chroman compound, as well as preparation method and application thereof
CN103450142B (en) 2013-09-04 2015-03-25 浙江大学 Chroman compound as well as extracting method and application thereof
CN103585145A (en) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Application of Artoxanthochromane in preparation of prostate cancer treatment drugs
CN103690525A (en) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Application of Artoxanthochromane in preparation of medicine for treating tongue cancer
CN103638008B (en) 2013-12-02 2015-09-16 刘艳娇 The application of Artoxanthochromane in treatment skin carcinoma medicine
CN103705503A (en) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Applications of Artoxanthochromane in medicines treating breast cancer
EP2953938B1 (en) * 2014-02-07 2017-08-02 Novogen Ltd. Functionalised benzopyran compounds and use thereof

Also Published As

Publication number Publication date
US20160340329A1 (en) 2016-11-24
SG11201604490SA (en) 2016-07-28
PH12016501422A1 (en) 2016-08-31
AU2015213484A1 (en) 2015-09-17
US10370349B2 (en) 2019-08-06
IL241515B (en) 2019-06-30
RU2676766C2 (en) 2019-01-11
LT2953938T (en) 2017-10-10
RU2016133731A (en) 2018-03-12
MY195739A (en) 2023-02-08
CA2936012C (en) 2023-03-07
JP2017507175A (en) 2017-03-16
EP2953938A1 (en) 2015-12-16
BR112016018099A2 (en) 2017-08-08
ES2643407T3 (en) 2017-11-22
SI2953938T1 (en) 2018-01-31
WO2015117202A1 (en) 2015-08-13
MX368063B (en) 2019-09-18
NZ711603A (en) 2017-05-26
CN105980372A (en) 2016-09-28
RU2016133731A3 (en) 2018-08-08
KR20160110427A (en) 2016-09-21
BR112016018099B1 (en) 2022-10-11
PH12016501422B1 (en) 2016-08-31
US20180141925A1 (en) 2018-05-24
SA516371583B1 (en) 2019-04-18
CA2936012A1 (en) 2015-08-13
EP2953938A4 (en) 2016-08-10
SG11201506988TA (en) 2015-10-29
US9701655B2 (en) 2017-07-11
CL2016001937A1 (en) 2017-01-20
PT2953938T (en) 2017-10-09
HK1218914A1 (en) 2017-03-17
PL2953938T3 (en) 2017-12-29
CN108484559A (en) 2018-09-04
EP2953938B1 (en) 2017-08-02
AU2015213484B2 (en) 2015-11-05
KR102395543B1 (en) 2022-05-09
BR112016018099B8 (en) 2023-01-17
JP6570042B2 (en) 2019-09-04
IL241515A0 (en) 2015-11-30
CN105980372B (en) 2018-05-08
DK2953938T3 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
HK1249524A1 (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
NZ731467A (en) Anti-tim3 antibodies and methods of use
TW201613648A (en) Compounds and compositions for immunotherapy
MA39906A (en) Combination therapies for the treatment of cancer
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
IL253979B (en) Methods, compositions, and kits for treatment of cancer
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2016006726A (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy.
MX2016016881A (en) Antibodies binding axl.
MX2017006015A (en) Apilimod for use in the treatment of renal cancer.
MX2016009590A (en) Apilimod compositions and methods for using same.
EP3200815A4 (en) Methods and compositions for treating cancer
IL276733A (en) Use of eribulin in the treatment of cancer
MX2019013808A (en) Compounds for treatment of cancer.
MX2018000715A (en) Methods for treating cancer using apilimod.
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
PH12016501838A1 (en) Compounds and their methods of use
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
MX2017009608A (en) Anti-cancer compounds.
IL249860A0 (en) Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer
EP3160591A4 (en) Compositions and methods for treating cancer
GB2546703A (en) Compounds
ZA201403006B (en) Composition for use in treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration